Media stories about Synageva Biopharma Corp (NASDAQ:GEVA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synageva Biopharma Corp earned a news sentiment score of 0.01 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.5299529914903 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Synageva Biopharma Corp (NASDAQ:GEVA) remained flat at $238.60 during midday trading on Friday. Synageva Biopharma Corp has a 1-year low of $60.19 and a 1-year high of $239.20. The company has a 50-day moving average price of $215.15 and a 200-day moving average price of $131.31.

TRADEMARK VIOLATION WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at

About Synageva Biopharma Corp

Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency).

Receive News & Ratings for Synageva Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synageva Biopharma Corp and related companies with's FREE daily email newsletter.